Penn Capital Management’s ANI Pharmaceuticals ANIP Stock Holding History

Penn Capital Management’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$13.8M	Buy	179,716 +42,322	+31%	+$3.3M	1.07%	53
2025 Q4	$10.9M	Buy	137,394 +131,030	+2,059%	+$11.3M	0.87%	66
2025 Q3	$583K	Buy	6,364 +387	+6%	+$31.6K	0.04%	140
2025 Q2	$390K	Sell	5,977 -719	-11%	-$46.8K	0.03%	138
2025 Q1	$448K	Buy	+6,696	New	+$400K	0.04%	129
2014 Q4	–	Sell	-143,220	Closed	-$4.05M	–	295
2014 Q3	$4.05M	Sell	143,220 -110	-0.1%	-$3.3K	0.17%	166
2014 Q2	$4.94M	Buy	143,330 +25,086	+21%	+$787K	0.19%	150
2014 Q1	$3.71M	Buy	+118,244	New	+$3.14M	0.14%	168

Other funds holding ANIP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

GAM

Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Penn Capital Management's ANIP Position: Q1 2026 in Review

Penn Capital Management increased its ANI Pharmaceuticals (ANIP) stake by 31% in Q1 2026, buying an estimated $3.3M and bringing the position to 179,716 shares worth $13.8M. The position accounts for 1.07% of the portfolio, ranked #53.

Penn Capital Management first reported a position in ANIP in Q1 2014 and has held it in 8 quarters since. 280 funds tracked by Wall St. Rank hold ANIP as of Q1 2026.

Penn Capital Management held 179,716 shares of ANI Pharmaceuticals worth $13.8M as of Q1 2026.
Penn Capital Management bought 42,322 ANI Pharmaceuticals shares in Q1 2026, an estimated $3.3M.
ANI Pharmaceuticals made up 1.07% of Penn Capital Management's portfolio in Q1 2026, its #53 holding.
Penn Capital Management first reported a position in ANI Pharmaceuticals in Q1 2014 and has held it in 8 quarters since.
280 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2026.

Based on Penn Capital Management's 13F filing for Q1 2026, filed 7 May 2026.